Precigen (PGEN) Shares Outstanding (2012 - 2026)
Precigen (PGEN) posted quarterly Shares Outstanding (Entity) of $355.9 million for Q1 2026, up 20.59% year-over-year from $295.1 million in Q1 2025, and up 0.56% quarter-over-quarter from $353.9 million in Q4 2025.
Analysis
Precigen (PGEN) Shares Outstanding (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Shares Outstanding (Entity) for 15 consecutive years, with $355.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 20.59% year-over-year to $355.9 million; the TTM figure through Mar 2026 stood at $355.9 million (up 20.59% YoY), while the FY2025 annual figure was $353.9 million, up 20.84% from the prior year.
- Shares Outstanding (Entity) improved to $355.9 million in Q1 2026 per PGEN's latest filing, from $353.9 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $355.9 million in Q1 2026 and bottomed at $207.7 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $271.2 million across 5 years, with a median of $256.4 million in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) rose 23.18% — and 2024, when it advanced 0.36%.
- Precigen's Shares Outstanding (Entity) stood at $208.2 million in 2022, then rose by 23.18% to $256.4 million in 2023, then grew by 14.22% to $292.9 million in 2024, then rose by 20.84% to $353.9 million in 2025, then gained by 0.56% to $355.9 million in 2026.
- Business Quant data shows PGEN's Shares Outstanding (Entity) at $355.9 million in Q1 2026, $353.9 million in Q4 2025, and $353.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 356.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 356.89 Mn |
| Mar 31, 2026 | 354.29 Mn |
| Dec 31, 2025 | 312.98 Mn |
| Sep 30, 2025 | 307.17 Mn |
| Jun 30, 2025 | 296.43 Mn |
| Mar 31, 2025 | 293.88 Mn |
| Dec 31, 2024 | 267.73 Mn |
| Sep 30, 2024 | 275.88 Mn |
| Jun 30, 2024 | 252.37 Mn |
| Mar 31, 2024 | 249.22 Mn |
| Dec 31, 2023 | 244.54 Mn |
| Sep 30, 2023 | 248.52 Mn |
| Jun 30, 2023 | 248.00 Mn |
| Mar 31, 2023 | 229.77 Mn |
| Dec 31, 2022 | 200.36 Mn |
| Sep 30, 2022 | 200.67 Mn |
| Jun 30, 2022 | 200.46 Mn |
| Mar 31, 2022 | 199.63 Mn |
| Dec 31, 2021 | 197.76 Mn |
| Sep 30, 2021 | 199.18 Mn |